🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆
Updated 11 Aug 2026 · ClinicalTrials.gov

Clinical Trials in the UK

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

110
Recruiting now
160
Studies tracked
119
Cities with sites
Active Phase 2
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc. · started 2025-03-07
📍 Birmingham · London
NCT06744647 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca · started 2025-06-27
📍 Bradford · Cottingham · Glasgow · Harrow · London
NCT07082738 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Huntington Disease
Novartis Pharmaceuticals · started 2026-03-24
📍 Exeter · Aberdeen · Cambridge · Cardiff · Glasgow
NCT07326709 on ClinicalTrials.gov ↗
By invitation Phase 3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Cancer
AstraZeneca · started 2022-04-19
📍 London · Sheffield
NCT05303532 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company · started 2020-02-12
📍 Bristol · Liverpool · London · Oxford · Sheffield
NCT04088396 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
End Stage Kidney Disease
CSL Behring · started 2022-10-21
📍 Birmingham · Bradford · Coventry · Derby · Dorchester
NCT05485961 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
Myotonic Dystrophy 1
Sarepta Therapeutics, Inc. · started 2024-03-04
📍 London · Nottingham · Southampton
NCT06138743 on ClinicalTrials.gov ↗
Recruiting Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca · started 2025-03-27
📍 Bath · Cambridge · Leeds · London · Manchester
NCT06989112 on ClinicalTrials.gov ↗
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
ATTR Amyloidosis
AstraZeneca · started 2023-08-21
📍 London
NCT06355934 on ClinicalTrials.gov ↗
By invitation Phase 3
A Long-term Follow-up Study in Participants Who Received CTX001
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases
Vertex Pharmaceuticals Incorporated · started 2021-01-20
📍 London
NCT04208529 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
COPD
Uniquity One (UNI) · started 2024-08-14
📍 Wythenshawe · Bradford · High Wycombe · London
NCT06496620 on ClinicalTrials.gov ↗
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD · started 2025-05-07
📍 Belfast · London · Middlesex · Sunderland
NCT06662162 on ClinicalTrials.gov ↗
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Parkinson's Disease
Boston Scientific Corporation · started 2014-03-04
📍 Bristol · Glasgow · Liverpool · London · Newcastle
NCT02071134 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease
Avidity Biosciences, Inc. · started 2026-08
📍 Newcastle
NCT07587242 on ClinicalTrials.gov ↗
Recruiting Phase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
Recurrent Pericarditis, Heart Diseases, Pericarditis
Kiniksa Pharmaceuticals International, plc · started 2026-03-25
📍 London
NCT07288216 on ClinicalTrials.gov ↗
Recruiting
A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSmile® Aligners.
Malocclusion
Dentsply Sirona Implants and Consumables · started 2026-01-29
📍 Bexleyheath
NCT07290790 on ClinicalTrials.gov ↗
Active Phase 2
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated · started 2025-11-19
📍 Birmingham · London · Newcastle upon Tyne · Sheffield
NCT07161037 on ClinicalTrials.gov ↗
Active Phase 3
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Mirum Pharmaceuticals, Inc. · started 2024-10-14
📍 London
NCT06553768 on ClinicalTrials.gov ↗
Starting soon Phase 1/Phase 2
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics · started 2026-11
📍 Birmingham · Cambridge · London
NCT07032038 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer · started 2024-10-21
📍 Blackburn · Westcliff-on-Sea · Edinburgh · Glasgow · London
NCT06551324 on ClinicalTrials.gov ↗
Active Phase 3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Cardiovascular Disease
AstraZeneca · started 2025-05-28
📍 Chesterfield · Chippenham · Corby · Coventry · Harrow
NCT07000123 on ClinicalTrials.gov ↗
Active Phase 3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc. · started 2021-02-23
📍 Birmingham · Edinburgh · Glasgow · Leicester · Manchester
NCT04685135 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Kiniksa Pharmaceuticals International, plc · started 2025-07-25
📍 London · Southampton
NCT07010159 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics · started 2024-03-06
📍 Oxford · Sutton
NCT06242470 on ClinicalTrials.gov ↗
Recruiting
Inari VISION Registry
Pulmonary Embolism
Inari Medical · started 2025-03-07
📍 Bristol · Glasgow · London · Newcastle · Swindon
NCT06600542 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Immunovant Sciences GmbH · started 2024-12-17
📍 Birmingham · Bristol · Coventry · London · Cambridge
NCT06727604 on ClinicalTrials.gov ↗
By invitation Phase 1
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Neoplasms
USWM CT, LLC · started 2018-04-09
📍 London · Manchester · Sutton
NCT03391778 on ClinicalTrials.gov ↗
Recruiting
Patient Retrospective Outcomes (PRO)
Chronic Pain
Boston Scientific Corporation · started 2012-04-03
📍 Basildon · Bristol · Exeter · Leeds · London
NCT01550575 on ClinicalTrials.gov ↗
Recruiting
International Wilson's Disease Patient Registry (iWilson Registry)
Wilson's Disease
Orphalan · started 2022-06-29
📍 Leeds · London
NCT05239858 on ClinicalTrials.gov ↗
Recruiting Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
EPP, XLP
Tanabe Pharma America, Inc. · started 2021-08-10
📍 Manchester · London
NCT05005975 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Hoffmann-La Roche · started 2025-05-05
📍 Blackpool · Leicester · Shipley · Coventry · Northwood
NCT06965413 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Amyotrophic Lateral Sclerosis
Prilenia · started 2026-02-01
📍 London · Stoke-on-Trent
NCT07322003 on ClinicalTrials.gov ↗
Active Phase 3
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Breast Cancer
AstraZeneca · started 2021-06-22
📍 Edinburgh
NCT04739761 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche · started 2026-04-07
📍 Leicester · London · Manchester
NCT07405801 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Regeneron Pharmaceuticals · started 2024-10-30
📍 Liverpool · York · Bristol · London · Newcastle upon Tyne
NCT06541704 on ClinicalTrials.gov ↗
Recruiting Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary Biliary Cholangitis
Gilead Sciences · started 2023-09-07
📍 Hull · Ipswich · Leeds · London · Newcastle upon Tyne
NCT06051617 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder, NMOSD
Hoffmann-La Roche · started 2026-05-06
📍 London
NCT05199688 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics · started 2022-08-12
📍 Liverpool · Newcastle upon Tyne · Leeds · Bristol · London
NCT05524883 on ClinicalTrials.gov ↗
Active Phase 3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Crohn's Disease
Eli Lilly and Company · started 2020-06-22
📍 Cambridge · London · Cardiff
NCT04232553 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Solid Tumours
AstraZeneca · started 2026-03-17
📍 Cambridge · London · Sutton
NCT07446855 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Niemann-Pick Type C Disease
Azafaros B.V. · started 2025-06-30
📍 London · Manchester
NCT07082725 on ClinicalTrials.gov ↗
Recruiting
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Pain
Boston Scientific Corporation · started 2012-11-19
📍 Basildon · Bristol · Leeds · London · Middlesbrough
NCT01719055 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
ImCheck Therapeutics, an Ipsen company · started 2020-03-05
📍 Glasgow · London
NCT04243499 on ClinicalTrials.gov ↗
Active Phase 3
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Gorlin Syndrome
Sol-Gel Technologies, Ltd. · started 2024-03-17
📍 Birmingham · London · Salford
NCT06050122 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
Hoffmann-La Roche · started 2024-08-14
📍 London
NCT05861999 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Psoriatic Arthritis
Takeda · started 2025-03-10
📍 London · Coventry · Bradford · Harlow · Oxford
NCT06671496 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Primary Membranous Nephropathy
AstraZeneca · started 2026-03-28
📍 London · Manchester
NCT07571746 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)
Servier Bio-Innovation LLC · started 2024-08-07
📍 London · Manchester
NCT06162572 on ClinicalTrials.gov ↗
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Multiple Sclerosis
Biogen · started 2023-10-27
📍 Salford
NCT05658497 on ClinicalTrials.gov ↗
Active Phase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Influenza
ModernaTX, Inc. · started 2026-03-23
📍 Bristol · High Wycombe · Peterborough · Stockton-on-Tees · Bournemouth
NCT07496450 on ClinicalTrials.gov ↗
Active Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Neoplasms
USWM CT, LLC · started 2019-12-31
📍 London · Manchester
NCT03967223 on ClinicalTrials.gov ↗
Recruiting Phase 2
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Mediar Therapeutics · started 2025-05-05
📍 Birmingham · Cambridge · Edinburgh · Oxford
NCT06967805 on ClinicalTrials.gov ↗
Recruiting Phase 3
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca · started 2026-05-05
📍 Edinburgh · Hampshire · Leeds · London · Manchester
NCT07509151 on ClinicalTrials.gov ↗
Recruiting Phase 3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences · started 2025-05-30
📍 London · Salford · Sheffield · Southampton
NCT06963021 on ClinicalTrials.gov ↗
Recruiting Phase 3
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
X-linked Retinoschisis
Atsena Therapeutics Inc. · started 2023-08-22
📍 Oxford
NCT05878860 on ClinicalTrials.gov ↗
Active
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-04-29
📍 London · Manchester
NCT06883240 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
BeOne Medicines · started 2025-01-23
📍 Birmingham · Leeds
NCT06697184 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
PMV Pharmaceuticals, Inc · started 2020-10-29
📍 London · Newcastle upon Tyne
NCT04585750 on ClinicalTrials.gov ↗
Active
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular · started 2021-10-20
📍 Oxford
NCT05198674 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC · started 2024-12-02
📍 Bristol · Exeter · Newcastle · Norwich · Northamptonshire
NCT06667700 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Generalized Anxiety Disorder
Definium Therapeutics US, Inc. · started 2025-01-29
📍 Glasgow · Gosforth · London · Manchester · Sheffield
NCT06809595 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Contineum Therapeutics · started 2026-01-08
📍 Leicester · London · Southampton · Edinburgh · Perth
NCT07284459 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Visugromab in Cachexia International Trial
Cancer-associated Cachexia
CatalYm GmbH · started 2026-04-16
📍 Brighton · Cambridge · Dundee · Guildford · Manchester
NCT07112196 on ClinicalTrials.gov ↗
Active Phase 2
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Hoffmann-La Roche · started 2023-11-29
📍 London · Oxford
NCT06128564 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo · started 2025-02-27
📍 Birmingham · Cardiff · Dundee · Hull · Leeds
NCT06731478 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Adenovirus Infections
SymBio Pharmaceuticals · started 2026-03-17
📍 Birmingham · Leeds · London · Manchester · Newcastle upon Tyne
NCT07387367 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC · started 2024-10-21
📍 Bristol · London · Nottingham · Leeds · Leicester
NCT06623422 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Fabry Disease
Chiesi Farmaceutici S.p.A. · started 2025-07-29
📍 London
NCT06328608 on ClinicalTrials.gov ↗
Active Phase 1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Inozyme Pharma · started 2023-06-25
📍 Manchester
NCT05734196 on ClinicalTrials.gov ↗
Recruiting Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim · started 2024-08-30
📍 Antrim · Basildon · Belfast · Birmingham · Blackburn
NCT06531824 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-Small Cell Lung Cancer
Hoffmann-La Roche · started 2023-06-20
📍 Glasgow · London
NCT05789082 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Healthy Participants, Obesity
AstraZeneca · started 2026-03-30
📍 Harrow
NCT07511205 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-06-27
📍 London · Manchester
NCT06998524 on ClinicalTrials.gov ↗
Starting soon Phase 3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Chronic Kidney Disease
AstraZeneca · started 2026-08-28
📍 Aberdeen · Cardiff · Corby · Coventry · Dundee
NCT07753993 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Haemophilia A
Novo Nordisk A/S · started 2025-10-23
📍 Birmingham · London · Sheffield
NCT07220564 on ClinicalTrials.gov ↗
Active Phase 3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals · started 2013-07-26
📍 West Midlands · Edinburgh · London
NCT01892722 on ClinicalTrials.gov ↗
By invitation Phase 3
An Open-label Study of XEN1101 in Epilepsy
Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc. · started 2023-04-25
📍 Leeds · Cardiff · Birmingham · London · Oxford
NCT05718817 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb · started 2026-01-02
📍 Leicester · London
NCT07063745 on ClinicalTrials.gov ↗
Active Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hoffmann-La Roche · started 2022-10-26
📍 Glasgow · London · Nottingham · Oxford
NCT05169515 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc. · started 2023-02-14
📍 Cardiff · Wakefield · London · Oxford · Salford
NCT05667142 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Dravet Syndrome
Longboard Pharmaceuticals · started 2024-09-25
📍 Newcastle upon Tyne · Glasgow · London
NCT06660394 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc. · started 2023-05-02
📍 Cambridge · Leicester · Manchester · Sutton
NCT05800665 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines · started 2025-06-11
📍 Bournemouth · Headington · Leeds · London · Metropolitan Borough of Wirral
NCT06943872 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Advanced Solid Tumors
AstraZeneca · started 2025-11-25
📍 Newcastle upon Tyne · Sutton
NCT07161414 on ClinicalTrials.gov ↗
Recruiting Phase 3
OLE Study With Filgotinib in JIA
Juvenile Idiopathic Arthritis (JIA)
Alfasigma S.p.A. · started 2026-04-20
📍 London
NCT07553182 on ClinicalTrials.gov ↗
Recruiting Phase 2
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc. · started 2026-03-10
📍 Exeter · Cottingham · Leicester · Birmingham
NCT07194382 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Prostate Cancer
AstraZeneca · started 2026-01-27
📍 Cambridge
NCT07336446 on ClinicalTrials.gov ↗
Active Phase 2
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Multifocal Motor Neuropathy
Dianthus Therapeutics · started 2024-09-17
📍 London · Oxford · Salford
NCT06537999 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Epizyme, Inc. · started 2020-06-11
📍 Edinburgh · London · Bebington · Cornwell · Glasgow
NCT04224493 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi · started 2025-08-06
📍 Cambridge · Dundee · London · Glasgow · Bath
NCT07088068 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb · started 2026-03-12
📍 Aberdeen · Middlesbrough · Norwich · Sutton · Cambridge
NCT07361510 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC · started 2023-05-31
📍 London · Newcastle upon Tyne
NCT05714085 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche · started 2026-08-31
📍 Sheffield
NCT07298421 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Azafaros B.V. · started 2025-06-30
📍 London · Manchester
NCT07054515 on ClinicalTrials.gov ↗
By invitation Phase 2
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated · started 2025-04-28
📍 Glasgow · London · Sheffield
NCT06926621 on ClinicalTrials.gov ↗
Recruiting Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim · started 2024-09-17
📍 Aberdeen · Ashton in Makerfield · Bristol · Camberley · Edgbaston, Birmingham
NCT06632444 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo · started 2024-02-26
📍 Coventry · London · Nottingham
NCT06172478 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC · started 2025-08-21
📍 Birmingham · Sheffield · Southampton
NCT07058077 on ClinicalTrials.gov ↗
Active Phase 3
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. · started 2023-04-26
📍 Birmingham · Hull · London
NCT05774756 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA)
argenx · started 2025-12-19
📍 Cambridge · London · Oxford · Sheffield · Glasgow
NCT07287982 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Hemophilia A, Hemophilia B
Pfizer · started 2022-12-09
📍 Newcastle upon Tyne · Birmingham · London · Manchester
NCT05611801 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb · started 2025-09-11
📍 Truro · London · Belfast · Manchester · Nottingham
NCT06926868 on ClinicalTrials.gov ↗
Active Phase 3
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Treatment Resistant Depression
COMPASS Pathways · started 2023-02-14
📍 Bodmin · Chertsey · Chester · Doncaster · Exeter
NCT05711940 on ClinicalTrials.gov ↗
Recruiting Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC · started 2026-03-23
📍 Glasgow · London · Manchester
NCT07405164 on ClinicalTrials.gov ↗
Active Phase 3
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1
Inozyme Pharma · started 2025-03-26
📍 Manchester
NCT07473973 on ClinicalTrials.gov ↗
Active Phase 2
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Huntington Disease
Hoffmann-La Roche · started 2023-02-03
📍 Birmingham · Cambridge · Leeds · London · Oxford
NCT05686551 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics, Inc. · started 2026-04-21
📍 London
NCT07227207 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
HIV-1-infection
Gilead Sciences · started 2022-08-16
📍 Birmingham · Brighton · London
NCT05502341 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc. · started 2026-04-29
📍 Sutton
NCT07567846 on ClinicalTrials.gov ↗
Active Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer, Early Breast Cancer
AstraZeneca · started 2023-10-05
📍 Aberdeen · Burton-on-Trent · Cambridge · Derby · Guildford
NCT05952557 on ClinicalTrials.gov ↗
Active Phase 3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Transthyretin Amyloid Cardiomyopathy
Alexion Pharmaceuticals, Inc. · started 2024-01-11
📍 Birmingham · Cardiff · Glasgow · Hexham · London
NCT06183931 on ClinicalTrials.gov ↗
Active Phase 2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Hoffmann-La Roche · started 2023-04-21
📍 London · Manchester
NCT05805501 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2026-05-04
📍 Swansea
NCT07513376 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche · started 2023-06-01
📍 Leicester · Surrey
NCT05862285 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC · started 2021-05-12
📍 Cambridge · Glasgow · London · Newcastle upon Tyne · Sheffield
NCT07218029 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC · started 2025-05-13
📍 Cambridge · Exeter · Northwood · Sutton · Devon
NCT06925737 on ClinicalTrials.gov ↗
Recruiting Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim · started 2024-11-07
📍 Aberdeen · Bristol · Camberley · Derby · Edgbaston, Birmingham
NCT06632457 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb · started 2026-03-16
📍 Manchester · Newcastle upon Tyne · Birmingham · Cambridge · Cardiff
NCT07361497 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals · started 2025-06-23
📍 Sheffield · Leeds · London · Swansea
NCT06846281 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
argenx · started 2024-04-16
📍 Glasgow · Leeds
NCT06298552 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC · started 2026-04-09
📍 Withington
NCT07489495 on ClinicalTrials.gov ↗
Active Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation · started 2023-09-25
📍 London · Manchester · Oxford
NCT05936359 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
Regeneron Pharmaceuticals · started 2023-12-12
📍 Truro · Plymouth · Bournemouth · Glasgow · Norwich
NCT06091254 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Obesity, Weight Gain
Eli Lilly and Company · started 2024-06-03
📍 Cambridge · Glagow · Leeds · Leicester · Liverpool
NCT06439277 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
Homocystinuria
Travere Therapeutics, Inc. · started 2023-12-28
📍 Birmingham · London · Salford
NCT06247085 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Neoplasm Malignant
Merck Sharp & Dohme LLC · started 2025-12-04
📍 London · Manchester
NCT07209111 on ClinicalTrials.gov ↗
Recruiting Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC · started 2024-06-24
📍 Bristol · Truro · London · Edinburgh · Leeds
NCT06393374 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc. · started 2023-01-23
📍 London
NCT04782258 on ClinicalTrials.gov ↗
Active Phase 3
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
Neuroendocrine Tumors
ITM Solucin GmbH · started 2017-02-02
📍 London · Manchester
NCT03049189 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim · started 2025-12-09
📍 Birmingham · Bristol · Glasgow · Liverpool · London
NCT07107945 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-03-16
📍 Truro · London · Nottingham · Taunton · Birmingham
NCT06841354 on ClinicalTrials.gov ↗
Recruiting Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim · started 2025-07-22
📍 Birmingham · Blackburn · Bournemouth · Bradford · Bristol
NCT07064473 on ClinicalTrials.gov ↗
Active
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Hemophilia B
Regeneron Pharmaceuticals · started 2024-01-17
📍 Southampton · London
NCT05568459 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines · started 2025-08-27
📍 Cambridge · Dundee · Metropolitan Borough of Wirral
NCT07043400 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
Merck Sharp & Dohme LLC · started 2026-04-23
📍 Cambridge
NCT07419295 on ClinicalTrials.gov ↗
Active Phase 3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
CLL
BeOne Medicines · started 2023-11-11
📍 Bournemouth · Canterbury · Headington · Leeds · Liverpool
NCT06073821 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC · started 2022-01-14
📍 Aberdeen · Truro · London-Camden
NCT05139017 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company · started 2025-03-27
📍 Birmingham · East Sussex · Huddersfield · London · Manchester
NCT06890598 on ClinicalTrials.gov ↗
Recruiting Phase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc. · started 2025-04-17
📍 Cottingham · Birmingham · Cambridge · Leicester · London
NCT06951217 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis · started 2025-07-21
📍 Birmingham · Cardiff · Glasgow · Liverpool · London
NCT06943755 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Dravet Syndrome
UCB BIOSCIENCES, Inc. · started 2024-05-21
📍 Glasgow · London
NCT06118255 on ClinicalTrials.gov ↗
Recruiting Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals · started 2025-04-30
📍 Chichester · London · Manchester · Tyne and Wear
NCT06813911 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC · started 2025-04-09
📍 Cambridge · Edinburgh · Preston · London · Sutton
NCT06824467 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen · started 2025-07-16
📍 Cambridge · Edinburgh · Leicester · Newcastle upon Tyne
NCT06570798 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda · started 2025-08-14
📍 Leicester · Southampton · Southwark · Liverpool · Glasgow
NCT06948318 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals · started 2019-10-03
📍 Newcastle upon Tyne · Cardiff · London
NCT03955445 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca · started 2026-05-06
📍 Cambridge · London · Manchester
NCT07427394 on ClinicalTrials.gov ↗
Active Phase 2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC · started 2022-07-21
📍 Truro · London · Oxford · Manchester
NCT05458297 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
CLL, Chronic Lymphocytic Leukemia
BeOne Medicines · started 2025-04-10
📍 Aberdeen · Birmingham · Bournemouth · London · Southampton
NCT06846671 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pridopidine Phase 3 Study in Huntington's Disease
Huntington Disease
Prilenia · started 2026-07-01
📍 Aberdeen · Birmingham · Cardiff · Liverpool · Newcastle upon Tyne
NCT07609108 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC · started 2023-12-13
📍 Bristol · Lancaster · London · Oxford · Newmarket
NCT06136559 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda · started 2025-02-27
📍 Leicester · Southampton · Southwark · Liverpool · Glasgow
NCT06722235 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-06-30
📍 London · Dundee · Huddersfield · Colchester · Orpington
NCT06966700 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines · started 2021-09-16
📍 Headington · London · Sutton · Truro
NCT04973605 on ClinicalTrials.gov ↗
Active Phase 3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Obesity
Novo Nordisk A/S · started 2023-07-07
📍 Birmingham · Bristol · Leeds · Liverpool · Southampton
NCT05726227 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Neoplasms, Child, Adolescent
Eli Lilly and Company · started 2020-01-22
📍 London · Manchester
NCT05999994 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC · started 2024-07-24
📍 London · Sutton · Glasgow · Leeds · Manchester
NCT06459180 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Breast Cancer
Eli Lilly and Company · started 2022-05-11
📍 London · Sutton
NCT05307705 on ClinicalTrials.gov ↗
Recruiting Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company · started 2025-09-02
📍 Belfast · Blackpool · Bodelwyddan · Bradford-on-Avon · Bristol
NCT07157774 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company · started 2021-05-26
📍 London · Oxford · Sheffield
NCT04844606 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 117 Manchester · 36 Birmingham · 34 Glasgow · 30 Leeds · 29 Cambridge · 25 Oxford · 23 Bristol · 20 Newcastle upon Tyne · 19 Sheffield · 17 Leicester · 16 Liverpool · 15 Cardiff · 14 Southampton · 14 Sutton · 14 Edinburgh · 12

Browse by condition

Chronic Lymphocytic Leukemia · 5 Obesity · 4 Huntington Disease · 3 Advanced Solid Tumor · 3 Neoplasms · 3 Breast Cancer · 3 CLL · 3 Cancer · 2 Recurrent Pericarditis · 2 Pericarditis · 2 Metastatic Cancer · 2 Crohn's Disease · 2 Niemann-Pick Type C Disease · 2 Non-small Cell Lung Cancer (NSCLC) · 2 Multiple Sclerosis · 2 Idiopathic Pulmonary Fibrosis · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk (Accessed: 12 August 2026).

Embed this data ↗

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.